Abstract: A method is disclosed for the in vitro growth and development of cells obtained from the follicles of a mammal to reproductively competent oocytes. By incubating these cells, which comprise small and medium oocytes, in a series of specific hormone-supplemented tissue culture media as described herein, they can be induced to grow and develop into reproductively competent oocytes. After a further maturation step in which chromosome number reduction occurs, the oocytes are fertilizable.

Abstract: A work space management system for dividing a space into separate work areas comprising a wall system having a rigid framework formed of rigid rectangular frames rigidly joined together at the edges thereof to form at least one work area, wire management elements secured to the frames for communication and power wiring and a plurality of selectively relocatable modular tiles removably hanging on the frames. Some of the wire management elements are secured to the bottom or baseline of the frames and some of the wire management elements are removably secured to a waistline or midportion of at least some of the frames. The frames can extend to a waist height, a seated height, to a standing or full floor to ceiling height in a modular stepped fashion. Decorative and functional modular tiles are sized to fit on the frames to substantially cover the frames, and are independently and removably mounted thereto. The tiles are of equal height and of variable modular width to cover the frames.

Abstract: A process is provided for the isolation of a mammalian blood protein fraction or derivative thereof, herein termed the "Prol A" fraction. The process comprises a series of centrifugal separations of blood fractions under conditions which maintain the integrity of the desired material as it existed in vivo.The "Prol A" fraction is a new material which constitutes another aspect of the invention. Prol A, a protein or derivative thereof, is useful as a neoplastic tissue remission and prevention agent.

Abstract: A process is provided for the isolation of two protein fractions herein termed the "blocking protein fractions" or "Blocker I" and "Blocker II," from mammalian blood. The process comprises a series of centrifugal separations of blood fractions under conditions which maintain the integrity of the desired material as it existed in vivo. These blocking protein fractions are new materials and they constitute another aspect of the invention. Isolated Blocker I and Blocker II, which are natural proteins or derivatives thereof, are useful to prevent tissue implant rejection, and as standards for the determination of the tumor remission activity of other materials isolated from blood.

Abstract: A process is provided for the isolation of a mammalian blood protein fraction or derivative thereof, herein termed the "deblocking protein fraction" or "DPF". The process comprises a series of centrifugal separations of blood fractions under conditions which maintain the integrity of the desired material as it existed in vivo.The deblocking protein fraction is a new material and it constitutes another aspect of the disclosure. isolated DPF, a protein or derivative thereof, is useful as a neoplastic tissue remission and prevention agent.

Abstract: A process is provided for the isolation of a protein fraction herein termed the "blocking protein fraction" or "BPF", from mammalian blood. The process comprises a series of centrifugal separations of blood fractions under conditions which maintain the integrity of the desired material as it existed in vivo.The blocking protein fraction, is a new material and it constitutes another aspect of the disclosure. Isolated BPF, a natural protein or a derivative thereof, is useful to prevent tissue implant rejection, and as standard from the determination of the tumor remission activity of other materials isolated from blood.

Abstract: A process is provided for the isolation of a blood polypeptide fraction or derivatives thereof herein termed the "tumor complement fraction" or "TCF", from mammalian blood. The process comprises a series of centrifugal separations of blood fractions under conditions which maintain the integrity of the desired material as it existed in vivo.The Tumor Complement Fraction, is a new material and it constitutes another aspect of the disclosure. Isolated TCF, a natural polypeptide or derivative thereof, is useful as a neoplastic tissue remission and prevention agent.